SCHEMBL17016283

SCHEMBL17016283

c1ccc(-c2ccc3c4ccc(-c5cccc(-c6ccc7c(c6)c6ccc8c(ccn8-c8ccccc8)c6n7-c6ccccc6)c5)cc4c4ccccc4c3c2)cc1

nearest known ligand 0.34

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
L3MBTL1 Q9Y468 2/20 0.34
KDM4E B2RXH2 1/20 0.34
ATM Q13315 1/20 0.34
MAOB P27338 1/20 0.34
WNK1 Q9H4A3 1/20 0.32
HTR7 P34969 1/20 0.31
TSPO P30536 1/20 0.31
METTL3 Q86U44 2/20 0.31
METTL14 Q9HCE5 2/20 0.31
OPRM1 P35372 1/20 0.31
OPRD1 P41143 1/20 0.31
KMT2A Q03164 2/20 0.31
IL1R1 P14778 1/20 0.31
KDR P35968 1/20 0.30
NR4A2 P43354 1/20 0.30
MEN1 O00255 1/20 0.30
ALDH1A1 P00352 1/20 0.30
MAPT P10636 1/20 0.30
HTT P42858 1/20 0.30
LIMK1 P53667 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL17016287 0.99 L3MBTL1 (0.35) L3MBTL1KDM4EATMMAOBWNK1
SCHEMBL17016280 0.97 L3MBTL1 (0.36) L3MBTL1KDM4EATMMAOBWNK1
SCHEMBL17016281 0.97 L3MBTL1 (0.36) L3MBTL1KDM4EATMMAOBWNK1
SCHEMBL17016282 0.96 KDM4E (0.37) L3MBTL1KDM4EATMMAOBHTR7
SCHEMBL16613777 0.96 MAOB (0.36) L3MBTL1KDM4EATMMAOBWNK1
SCHEMBL16613708 0.95 MAOB (0.35) L3MBTL1KDM4EATMMAOBWNK1
SCHEMBL16613827 0.95 MAOB (0.35) L3MBTL1KDM4EATMMAOBWNK1
SCHEMBL17016277 0.95 L3MBTL1 (0.38) L3MBTL1KDM4EATMMAOBKMT2A
SCHEMBL16613860 0.94 MAOB (0.36) L3MBTL1KDM4EATMMAOBHTR7
SCHEMBL16613847 0.94 MAOB (0.37) L3MBTL1KDM4EATMMAOBHTR7

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9837618-B2 Compound and organic electroluminescence device including thesame DOOSAN CORPORATION (KR) 2017-12-05 US disclosed
US-9837618-B2 Compound and organic electroluminescence device including thesame DOOSAN CORPORATION (KR) 2017-12-05 US disclosed
US-20150236272-A1 NOVEL COMPOUND AND ORGANIC ELECTROLUMINESCENCE DEVICE INCLUDING THESAME DOOSAN CORPORATION (KR) 2015-08-20 US disclosed
US-20150236272-A1 NOVEL COMPOUND AND ORGANIC ELECTROLUMINESCENCE DEVICE INCLUDING THESAME DOOSAN CORPORATION (KR) 2015-08-20 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20150236272-A1 NOVEL COMPOUND AND ORGANIC ELECTROLUMINESCENCE DEVICE INCLUDING THESAME INMT, IDO1, IDO2 L3MBTL1 533/4885KDM4E 1286/4885ATM 3623/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.